209 related articles for article (PubMed ID: 18171452)
1. Children's and parents' perspectives on open-label use of placebos in the treatment of ADHD.
Sandler A; Glesne C; Geller G
Child Care Health Dev; 2008 Jan; 34(1):111-20. PubMed ID: 18171452
[TBL] [Abstract][Full Text] [Related]
2. Open-label use of placebos in the treatment of ADHD: a pilot study.
Sandler AD; Bodfish JW
Child Care Health Dev; 2008 Jan; 34(1):104-10. PubMed ID: 18171451
[TBL] [Abstract][Full Text] [Related]
3. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
Research Units on Pediatric Psychopharmacology Autism Network
Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life in methylphenidate-treated children with attention-deficit-hyperactivity disorder: results from a Taiwanese sample.
Yang P; Hsu HY; Chiou SS; Chao MC
Aust N Z J Psychiatry; 2007 Dec; 41(12):998-1004. PubMed ID: 17999272
[TBL] [Abstract][Full Text] [Related]
5. Critical influences affecting response to various treatments in young children with ADHD: a case series.
Heriot SA; Evans IM; Foster TM
Child Care Health Dev; 2008 Jan; 34(1):121-33. PubMed ID: 18171453
[TBL] [Abstract][Full Text] [Related]
6. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
[TBL] [Abstract][Full Text] [Related]
7. Are there placebo effects in the medication treatment of children with attention-deficit hyperactivity disorder?
Waschbusch DA; Pelham WE; Waxmonsky J; Johnston C
J Dev Behav Pediatr; 2009 Apr; 30(2):158-68. PubMed ID: 19363369
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
[TBL] [Abstract][Full Text] [Related]
9. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures.
Posey DJ; Aman MG; McCracken JT; Scahill L; Tierney E; Arnold LE; Vitiello B; Chuang SZ; Davies M; Ramadan Y; Witwer AN; Swiezy NB; Cronin P; Shah B; Carroll DH; Young C; Wheeler C; McDougle CJ
Biol Psychiatry; 2007 Feb; 61(4):538-44. PubMed ID: 17276750
[TBL] [Abstract][Full Text] [Related]
10. An n-of-1 trial service in clinical practice: testing the effectiveness of stimulants for attention-deficit/hyperactivity disorder.
Nikles CJ; Mitchell GK; Del Mar CB; Clavarino A; McNairn N
Pediatrics; 2006 Jun; 117(6):2040-6. PubMed ID: 16740846
[TBL] [Abstract][Full Text] [Related]
11. Effects of methylphenidate on quality of life in children with both developmental coordination disorder and ADHD.
Flapper BC; Schoemaker MM
Dev Med Child Neurol; 2008 Apr; 50(4):294-9. PubMed ID: 18352997
[TBL] [Abstract][Full Text] [Related]
12. Acute impact of immediate release methylphenidate administered three times a day on sleep in children with attention-deficit/hyperactivity disorder.
Corkum P; Panton R; Ironside S; Macpherson M; Williams T
J Pediatr Psychol; 2008 May; 33(4):368-79. PubMed ID: 18056144
[TBL] [Abstract][Full Text] [Related]
13. Treatment choices and experiences in attention deficit and hyperactivity disorder: relations to parents' beliefs and attributions.
Johnston C; Seipp C; Hommersen P; Hoza B; Fine S
Child Care Health Dev; 2005 Nov; 31(6):669-77. PubMed ID: 16207224
[TBL] [Abstract][Full Text] [Related]
14. Fenfluramine and methylphenidate in children with mental retardation and borderline IQ: clinical effects.
Aman MG; Kern RA; Osborne P; Tumuluru R; Rojahn J; del Medico V
Am J Ment Retard; 1997 Mar; 101(5):521-34. PubMed ID: 9083608
[TBL] [Abstract][Full Text] [Related]
15. Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United kingdom.
Secnik K; Matza LS; Cottrell S; Edgell E; Tilden D; Mannix S
Med Decis Making; 2005; 25(1):56-70. PubMed ID: 15673582
[TBL] [Abstract][Full Text] [Related]
16. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
Findling RL
Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
[TBL] [Abstract][Full Text] [Related]
17. Children's self-reports on perceived effects on taking stimulant medication for ADHD.
Thorell LB; Dahlström K
J Atten Disord; 2009 Mar; 12(5):460-8. PubMed ID: 18685139
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder.
Kahbazi M; Ghoreishi A; Rahiminejad F; Mohammadi MR; Kamalipour A; Akhondzadeh S
Psychiatry Res; 2009 Aug; 168(3):234-7. PubMed ID: 19439364
[TBL] [Abstract][Full Text] [Related]
19. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
[TBL] [Abstract][Full Text] [Related]
20. Attitudes toward attention-deficit hyperactivity disorder (ADHD) treatment: parents' and children's perspectives.
Berger I; Dor T; Nevo Y; Goldzweig G
J Child Neurol; 2008 Sep; 23(9):1036-42. PubMed ID: 18487521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
